星空体育官方入口网站网址大全-登录入口官网

#CDK#

85篇内容 | 1886人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2209758, encodeId=88482209e5872, content=<a href='/topic/show?id=d8dbe130197' target=_blank style='color:#2F92EE;'>#癌症#</a> <a href='/topic/show?id=09dc439915' target=_blank style='color:#2F92EE;'>#CDK#</a> <a href='/topic/show?id=1c48e783278' target=_blank style='color:#2F92EE;'>#细胞周期#</a> <a href='/topic/show?id=835f1154e890' target=_blank style='color:#2F92EE;'>#检验点#</a>, objectTitle=癌症生物学系列：肿瘤与细胞周期控制时钟, objectType=article, longId=829775, objectId=9359829e7545, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240613/1718272155109_1608702.png, objectUrl=/article/show_article.do?id=9359829e7545, replyNumber=0, likeNumber=28, createdTime=2024-06-13, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=9359829e7545, moduleTitle=癌症生物学系列：肿瘤与细胞周期控制时钟, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=9359829e7545)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1435566, encodeId=4dcf14355667f, content=<a href='/topic/show?id=09dc439915' target=_blank style='color:#2F92EE;'>#CDK#</a>, objectTitle=HR+HER2-晚期乳腺癌CDK4/6i失败后治疗模式新探索, objectType=article, longId=736714, objectId=1cd4e36714ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1cd4e36714ec, replyNumber=0, likeNumber=59, createdTime=2022-08-25, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1cd4e36714ec, moduleTitle=HR+HER2-晚期乳腺癌CDK4/6i失败后治疗模式新探索, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=1cd4e36714ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1435565, encodeId=16741435565be, content=<a href='/topic/show?id=09dc439915' target=_blank style='color:#2F92EE;'>#CDK#</a>, objectTitle=CDK4/6i不良反应管理手册来了！这篇总结的很全哦~, objectType=article, longId=733755, objectId=afe2e3375555, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=afe2e3375555, replyNumber=0, likeNumber=72, createdTime=2022-07-30, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=afe2e3375555, moduleTitle=CDK4/6i不良反应管理手册来了！这篇总结的很全哦~, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=afe2e3375555)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1435564, encodeId=59c51435564a7, content=<a href='/topic/show?id=09dc439915' target=_blank style='color:#2F92EE;'>#CDK#</a>, objectTitle=Clin Cancer Res：氟维司群联合维奈托克治疗CDK4/6抑制剂难治性ER+转移性乳腺癌, objectType=article, longId=730361, objectId=69abe303613d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=69abe303613d, replyNumber=0, likeNumber=63, createdTime=2022-06-25, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=69abe303613d, moduleTitle=Clin Cancer Res：氟维司群联合维奈托克治疗CDK4/6抑制剂难治性ER+转移性乳腺癌, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=69abe303613d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1435562, encodeId=4219143556203, content=<a href='/topic/show?id=09dc439915' target=_blank style='color:#2F92EE;'>#CDK#</a>, objectTitle=ASCO 2022 | MAINTAIN全新思路：CDK4/6抑制剂失败后跨线再战，瑞博西利仍可带来PFS获益！, objectType=article, longId=729096, objectId=317ae2909688, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=317ae2909688, replyNumber=0, likeNumber=0, createdTime=2022-06-12, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=317ae2909688, moduleTitle=ASCO 2022 | MAINTAIN全新思路：CDK4/6抑制剂失败后跨线再战，瑞博西利仍可带来PFS获益！, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=317ae2909688)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1435563, encodeId=f0491435563ef, content=<a href='/topic/show?id=09dc439915' target=_blank style='color:#2F92EE;'>#CDK#</a>, objectTitle=ASCO 2022 | PALOMA-2研究最终数据出炉：全球首款CDK4/6抑制剂哌柏西利再受挫！ , objectType=article, longId=729095, objectId=d5c5e2909563, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d5c5e2909563, replyNumber=0, likeNumber=63, createdTime=2022-06-12, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d5c5e2909563, moduleTitle=ASCO 2022 | PALOMA-2研究最终数据出炉：全球首款CDK4/6抑制剂哌柏西利再受挫！ , moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=d5c5e2909563)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1435561, encodeId=9e4e1435561f9, content=<a href='/topic/show?id=09dc439915' target=_blank style='color:#2F92EE;'>#CDK#</a>, objectTitle=Lancet Neurol：Ganaxolone治疗CDKL5缺乏症的疗效, objectType=article, longId=726277, objectId=87fde26277dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=87fde26277dc, replyNumber=0, likeNumber=74, createdTime=2022-05-08, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=87fde26277dc, moduleTitle=Lancet Neurol：Ganaxolone治疗CDKL5缺乏症的疗效, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=87fde26277dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1435560, encodeId=05e11435560e8, content=<a href='/topic/show?id=09dc439915' target=_blank style='color:#2F92EE;'>#CDK#</a>, objectTitle=LEUKEMIA：Erk1/2i 和 CDK4/6i 联合治疗复发难治性多发性骨髓瘤, objectType=article, longId=299159, objectId=5c4f2991594a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5c4f2991594a, replyNumber=0, likeNumber=50, createdTime=2022-02-20, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5c4f2991594a, moduleTitle=LEUKEMIA：Erk1/2i 和 CDK4/6i 联合治疗复发难治性多发性骨髓瘤, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=5c4f2991594a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1435559, encodeId=0e09143555970, content=<a href='/topic/show?id=09dc439915' target=_blank style='color:#2F92EE;'>#CDK#</a>, objectTitle=Br J Cancer：CDK4/6抑制剂在恶性胸膜间皮瘤临床前模型中的疗效分析, objectType=article, longId=219389, objectId=f5d0219389bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f5d0219389bc, replyNumber=0, likeNumber=65, createdTime=2021-10-29, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f5d0219389bc, moduleTitle=Br J Cancer：CDK4/6抑制剂在恶性胸膜间皮瘤临床前模型中的疗效分析, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=f5d0219389bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1435558, encodeId=a349143555847, content=<a href='/topic/show?id=09dc439915' target=_blank style='color:#2F92EE;'>#CDK#</a>, objectTitle=Lancet Oncol：CDKI联合氟维司群有望成为激素受体阳性、HER2阴性的晚期乳腺癌的标准治疗方案！, objectType=article, longId=219161, objectId=aee8219161b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aee8219161b7, replyNumber=0, likeNumber=63, createdTime=2021-10-25, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aee8219161b7, moduleTitle=Lancet Oncol：CDKI联合氟维司群有望成为激素受体阳性、HER2阴性的晚期乳腺癌的标准治疗方案！, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=aee8219161b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1435555, encodeId=3f1b143555506, content=<a href='/topic/show?id=09dc439915' target=_blank style='color:#2F92EE;'>#CDK#</a>, objectTitle=Clin Cancer Res:瑞博西尼（ribociclib）联合依西美坦+依维莫司治疗CDK4/6抑制剂治疗进展的HR+/HER2-晚期乳腺癌的疗效和安全性：I/II期TRINITI-1研究, objectType=article, longId=213367, objectId=676e21336e25, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=676e21336e25, replyNumber=0, likeNumber=62, createdTime=2021-06-29, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=676e21336e25, moduleTitle=Clin Cancer Res:瑞博西尼（ribociclib）联合依西美坦+依维莫司治疗CDK4/6抑制剂治疗进展的HR+/HER2-晚期乳腺癌的疗效和安全性：I/II期TRINITI-1研究, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=676e21336e25)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1435554, encodeId=fb511435554a1, content=<a href='/topic/show?id=09dc439915' target=_blank style='color:#2F92EE;'>#CDK#</a>, objectTitle=Cell Reports：CDK抑制剂与免疫疗法强强联手，复发性乳腺癌有救了, objectType=article, longId=211360, objectId=ef47211360b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ef47211360b9, replyNumber=0, likeNumber=54, createdTime=2021-05-17, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ef47211360b9, moduleTitle=Cell Reports：CDK抑制剂与免疫疗法强强联手，复发性乳腺癌有救了, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=ef47211360b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1435557, encodeId=e9b0143555e9e, content=<a href='/topic/show?id=09dc439915' target=_blank style='color:#2F92EE;'>#CDK#</a>, objectTitle=2021BOC/BOA：殷咏梅教授解读CDK4/6抑制剂阿贝西利中国临床实践数据，以期提高可及性, objectType=article, longId=211179, objectId=0aac2111e9ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0aac2111e9ad, replyNumber=0, likeNumber=56, createdTime=2021-05-13, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0aac2111e9ad, moduleTitle=2021BOC/BOA：殷咏梅教授解读CDK4/6抑制剂阿贝西利中国临床实践数据，以期提高可及性, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=0aac2111e9ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1435553, encodeId=2f241435553ff, content=<a href='/topic/show?id=09dc439915' target=_blank style='color:#2F92EE;'>#CDK#</a>, objectTitle=JNCCN：乳腺癌患者CDK4/6抑制剂哌柏西利进展后使用阿贝西利治疗的疗效：多中心临床经验, objectType=article, longId=211171, objectId=30eb2111e1ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=30eb2111e1ef, replyNumber=0, likeNumber=56, createdTime=2021-05-13, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=30eb2111e1ef, moduleTitle=JNCCN：乳腺癌患者CDK4/6抑制剂哌柏西利进展后使用阿贝西利治疗的疗效：多中心临床经验, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=30eb2111e1ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1435556, encodeId=0d8e143555634, content=<a href='/topic/show?id=09dc439915' target=_blank style='color:#2F92EE;'>#CDK#</a>, objectTitle=2021BOC/BOA：江泽飞教授解读CDK4/6抑制剂阿贝西利中国数据，期待惠及更多乳腺癌患者, objectType=article, longId=210931, objectId=06062109315d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=06062109315d, replyNumber=0, likeNumber=45, createdTime=2021-05-09, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=06062109315d, moduleTitle=2021BOC/BOA：江泽飞教授解读CDK4/6抑制剂阿贝西利中国数据，期待惠及更多乳腺癌患者, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=06062109315d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1435552, encodeId=8ecc14355523b, content=<a href='/topic/show?id=09dc439915' target=_blank style='color:#2F92EE;'>#CDK#</a>, objectTitle=Cancer：BRCA1/2-、CDK12-和ATM-突变的转移去势抵抗性前列腺癌的差异化治疗结果 , objectType=article, longId=209040, objectId=19e420904055, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19e420904055, replyNumber=0, likeNumber=99, createdTime=2021-03-28, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19e420904055, moduleTitle=Cancer：BRCA1/2-、CDK12-和ATM-突变的转移去势抵抗性前列腺癌的差异化治疗结果 , moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=19e420904055)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1435551, encodeId=9ead143555183, content=<a href='/topic/show?id=09dc439915' target=_blank style='color:#2F92EE;'>#CDK#</a>, objectTitle=科学致胜，共克癌症 ——全球CDK4/6抑制剂持续响应“世界癌症日” 助力中国患者对抗晚期乳腺癌, objectType=article, longId=206821, objectId=c8452068210e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c8452068210e, replyNumber=0, likeNumber=54, createdTime=2021-02-07, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c8452068210e, moduleTitle=科学致胜，共克癌症 ——全球CDK4/6抑制剂持续响应“世界癌症日” 助力中国患者对抗晚期乳腺癌, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c8452068210e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1435550, encodeId=c4d21435550f8, content=<a href='/topic/show?id=09dc439915' target=_blank style='color:#2F92EE;'>#CDK#</a>, objectTitle=Prostate Cancer P D：通过CRISPR失活CDKN2A位点和端粒酶的表达实现人原代前列腺上皮细胞永生化, objectType=article, longId=200745, objectId=b32a200e45a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b32a200e45a7, replyNumber=0, likeNumber=66, createdTime=2020-09-18, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b32a200e45a7, moduleTitle=Prostate Cancer P D：通过CRISPR失活CDKN2A位点和端粒酶的表达实现人原代前列腺上皮细胞永生化, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=b32a200e45a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1435549, encodeId=184014355498f, content=<a href='/topic/show?id=09dc439915' target=_blank style='color:#2F92EE;'>#CDK#</a>, objectTitle=甘李药业CDK4/6抑制剂获FDA孤儿药资格，治疗恶性胶质瘤, objectType=article, longId=200588, objectId=285f20058863, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=285f20058863, replyNumber=0, likeNumber=55, createdTime=2020-09-13, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=285f20058863, moduleTitle=甘李药业CDK4/6抑制剂获FDA孤儿药资格，治疗恶性胶质瘤, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=285f20058863)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1435548, encodeId=acb8143554815, content=<a href='/topic/show?id=09dc439915' target=_blank style='color:#2F92EE;'>#CDK#</a>, objectTitle=Cell Death & Disease：新研究揭示LncRNA CDKN2B-AS1/miR-141/cyclin D网络能调控肾细胞癌的肿瘤进展和转移, objectType=article, longId=200459, objectId=dabd200459a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dabd200459a9, replyNumber=0, likeNumber=56, createdTime=2020-09-11, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dabd200459a9, moduleTitle=Cell Death & Disease：新研究揭示LncRNA CDKN2B-AS1/miR-141/cyclin D网络能调控肾细胞癌的肿瘤进展和转移, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=dabd200459a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

CDK

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#癌症# #CDK# #细胞周期# #检验点#

癌症生物学系列：肿瘤与细胞周期控制时钟

2024-06-13发表于上海

zhouqu_8 (审核中...)

前往app查看评论内容

#CDK#

HR+HER2-晚期乳腺癌CDK4/6i失败后治疗模式新探索

2022-08-25

zhouqu_8 (审核中...)

前往app查看评论内容

#CDK#

CDK4/6i不良反应管理手册来了！这篇总结的很全哦~

2022-07-30

zhouqu_8 (审核中...)

前往app查看评论内容

#CDK#

Clin Cancer Res：氟维司群联合维奈托克治疗CDK4/6抑制剂难治性ER+转移性乳腺癌

2022-06-25

zhouqu_8 (审核中...)

前往app查看评论内容

#CDK#

ASCO 2022 | MAINTAIN全新思路：CDK4/6抑制剂失败后跨线再战，瑞博西利仍可带来PFS获益！

2022-06-12

zhouqu_8 (审核中...)

前往app查看评论内容

#CDK#

ASCO 2022 | PALOMA-2研究最终数据出炉：全球首款CDK4/6抑制剂哌柏西利再受挫！

2022-06-12

zhouqu_8 (审核中...)

前往app查看评论内容

#CDK#

Lancet Neurol：Ganaxolone治疗CDKL5缺乏症的疗效

2022-05-08

zhouqu_8 (审核中...)

前往app查看评论内容

#CDK#

LEUKEMIA：Erk1/2i 和 CDK4/6i 联合治疗复发难治性多发性骨髓瘤

2022-02-20

zhouqu_8 (审核中...)

前往app查看评论内容

#CDK#

Br J Cancer：CDK4/6抑制剂在恶性胸膜间皮瘤临床前模型中的疗效分析

2021-10-29

zhouqu_8 (审核中...)

前往app查看评论内容

#CDK#

Lancet Oncol：CDKI联合氟维司群有望成为激素受体阳性、HER2阴性的晚期乳腺癌的标准治疗方案！

2021-10-25

zhouqu_8 (审核中...)

前往app查看评论内容

#CDK#

Clin Cancer Res:瑞博西尼（ribociclib）联合依西美坦+依维莫司治疗CDK4/6抑制剂治疗进展的HR+/HER2-晚期乳腺癌的疗效和安全性：I/II期TRINITI-1研究

2021-06-29

zhouqu_8 (审核中...)

前往app查看评论内容

#CDK#

Cell Reports：CDK抑制剂与免疫疗法强强联手，复发性乳腺癌有救了

2021-05-17

zhouqu_8 (审核中...)

前往app查看评论内容

#CDK#

2021BOC/BOA：殷咏梅教授解读CDK4/6抑制剂阿贝西利中国临床实践数据，以期提高可及性

2021-05-13

zhouqu_8 (审核中...)

前往app查看评论内容

#CDK#

JNCCN：乳腺癌患者CDK4/6抑制剂哌柏西利进展后使用阿贝西利治疗的疗效：多中心临床经验

2021-05-13

zhouqu_8 (审核中...)

前往app查看评论内容

#CDK#

2021BOC/BOA：江泽飞教授解读CDK4/6抑制剂阿贝西利中国数据，期待惠及更多乳腺癌患者

2021-05-09

zhouqu_8 (审核中...)

前往app查看评论内容

#CDK#

Cancer：BRCA1/2-、CDK12-和ATM-突变的转移去势抵抗性前列腺癌的差异化治疗结果

2021-03-28

zhouqu_8 (审核中...)

前往app查看评论内容

#CDK#

科学致胜，共克癌症 ——全球CDK4/6抑制剂持续响应“世界癌症日” 助力中国患者对抗晚期乳腺癌

2021-02-07

zhouqu_8 (审核中...)

前往app查看评论内容

#CDK#

Prostate Cancer P D：通过CRISPR失活CDKN2A位点和端粒酶的表达实现人原代前列腺上皮细胞永生化

2020-09-18

zhouqu_8 (审核中...)

前往app查看评论内容

#CDK#

甘李药业CDK4/6抑制剂获FDA孤儿药资格，治疗恶性胶质瘤

2020-09-13

zhouqu_8 (审核中...)

前往app查看评论内容

#CDK#

Cell Death & Disease：新研究揭示LncRNA CDKN2B-AS1/miR-141/cyclin D网络能调控肾细胞癌的肿瘤进展和转移

2020-09-11

科室
- - 订阅+
  - 更多科室
工具
服务